Dermelloa

Independent breakdown

MelApp & Mole Detective (FTC-sanctioned)

Not recommended

Technology: Photo + questionnaire "melanoma risk" calculators (now discontinued)

What it actually does technically

These apps asked users to photograph a mole and answer questions, then output a low / medium / high melanoma risk. They were marketed as able to assess melanoma risk, including in early stages.

What peer-reviewed research says about accuracy

There was no adequate scientific evidence the apps could do what they claimed. They are a documented example of consumer skin tech making medical claims it could not support.

Known limitations the company doesn't advertise

A risk score from a snapshot can falsely reassure someone who actually has a melanoma — a potentially deadly failure mode.

Who funded the studies they cite

Funding source transparency is a standard part of our review. Company-funded research is not automatically invalid, but it warrants closer scrutiny. We note it here so you can weigh the evidence yourself.

This is the accountability lesson: in 2015 the U.S. FTC charged the marketers with deceptive advertising for unsubstantiated melanoma-detection claims. Both settled — Health Discovery Corp. (MelApp) and New Consumer Solutions (Mole Detective) — and were barred from making such claims without scientific evidence.

Plain English verdict

Not recommended

Included as a cautionary case study, not a recommendation. These melanoma-risk apps were sanctioned by the U.S. FTC in 2015 for deceptive claims they could not back up. They are the clearest example of why "AI can detect your skin cancer" marketing deserves deep skepticism — a falsely reassuring result can be dangerous.

Worth it if you want

  • +Understanding why melanoma-detection claims demand FDA-level evidence, not marketing copy

Not worth it if

  • Any actual skin-cancer concern — see a board-certified dermatologist